Turning Point Therapeutics (TPTX) Return on Equity ROE from the second quarter 2022 to second quarter 2021 and annually, average high and low, overall ranking from Jun 30 2022 to Jun 30 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Turning Point Therapeutics Inc.  (NASDAQ: TPTX)

Turning Point Therapeutics's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Turning Point Therapeutics in the second quarter 2022?
Turning Point Therapeutics Inc. recorded a cumulative net loss of $-342 million during 12 months ending in the second quarter 2022, resulting in a negative return on equity (ROE) of -37.45%.

Within the Major Pharmaceutical Preparations industry 193 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2022 from 0 to 3502.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter
Y / Y Equity Change -25.71 % -19.05 % -14.01 % 45 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -342 -275 -237 -205 -157
Return On Equity (TTM) -37.45 % -28.04 % -22.85 % -19.13 % -15.76 %
TPTX's Total Ranking # 3502 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 793 891 954 1,017 1,068
Seq. Equity Change -11.03 % -6.61 % -6.18 % -4.7 % -3.06 %
Seq. Net Income Change - - - - -

Back to TPTX Management Effectiveness >> TPTX's 5 Years Annual ROE >> Compare TPTX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 194
Sector # 477
Overall # 3502

Return On Equity Statistics
High Average Low
-15.75 %
-26.2 %
-37.45 %
(Jun 30 2021)   (Jun 30 2022)





TPTX Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019

Total Equity in Millions 954 1,110 404 0 0
Y / Y Equity Change -14.01 % 174.49 % - - -
Net Income in Millions -237 -157 -72 0 0
Y / Y Net Income Change - - - - -
Return On Equity -24.78 % -14.17 % -17.84 % - -

Back to TPTX Management Effectiveness >> TPTX's 5 Years Annual ROE >> Compare TPTX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TPTX's' Return on Equity at Yahoo Finance
TPTX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TPTX's Competitors
Subscribers only: Roe for Turning Point Therapeutics's Suppliers
Subscribers only: Return On Equity for TPTX's Customers




Companies with similar Return On Equity at Jun 30 2022, within Healthcare Sector ROE

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.